𝔖 Bobbio Scriptorium
✦   LIBER   ✦

NOA-05 phase 2 trial of procarbazine and lomustine therapy in gliomatosis cerebri

✍ Scribed by Martin Glas; Oliver Bähr; Jörg Felsberg; Katja Rasch; Dorothee Wiewrodt; Martin Schabet; Matthias Simon; Horst Urbach; Joachim P. Steinbach; Johannes Rieger; Rolf Fimmers; Michael Bamberg; Thomas Nägele; Guido Reifenberger; Michael Weller; Ulrich Herrlinger MD; for the Neuro-Oncology Group of the German Cancer Society

Publisher
John Wiley and Sons
Year
2011
Tongue
English
Weight
174 KB
Volume
70
Category
Article
ISSN
0364-5134

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Phase 2 randomized trial of primary endo
Phase 2 randomized trial of primary endocrine therapy versus chemotherapy in postmenopausal patients with estrogen receptor-positive breast cancer
✍ Vladimir F. Semiglazov; Vladislav V. Semiglazov; Garik A. Dashyan; Elena K. Zilt 📂 Article 📅 2007 🏛 John Wiley and Sons 🌐 English ⚖ 194 KB

## Abstract ## BACKGROUND. Few studies have compared primary neoadjuvant endocrine therapy with neoadjuvant chemotherapy in breast cancer patients. The need for preoperative chemotherapy with doxorubicin or taxanes may be reduced in postmenopausal patients with estrogen receptor (ER)‐positive and/

Completion of premaintenance phases in t
Completion of premaintenance phases in total therapies 2 and 3 improves clinical outcomes in multiple myeloma : An important variable to be considered in clinical trial designs
✍ Bart Barlogie; Jeff Haessler; Mauricio Pineda-Roman; Elias Anaissie; Frits van R 📂 Article 📅 2008 🏛 John Wiley and Sons 🌐 English ⚖ 297 KB

## Abstract ## BACKGROUND. Total Therapy (TT) programs are complex and their execution over the course of several years is fraught with patient attrition due to failure and toxicity of therapy and patient/physician acceptance. ## METHODS. The impact of completion versus noncompletion of intended

Combination therapy with fludarabine and
Combination therapy with fludarabine and rituximab followed by alemtuzumab in the first-line treatment of patients with chronic lymphocytic leukemia or small lymphocytic lymphoma : A phase 2 trial of the Minnie Pearl Cancer Research Network
✍ John D. Hainsworth; Elizabeth R. Vazquez; David R. Spigel; Eric Raefsky; James D 📂 Article 📅 2008 🏛 John Wiley and Sons 🌐 English ⚖ 106 KB 👁 2 views

## Abstract ## BACKGROUND The purpose of the current study was to evaluate the efficacy and toxicity of the combination of fludarabine and rituximab, followed by alemtuzumab, as first‐line treatment for patients with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL). ## METHO

Efficacy and safety of the PPARγ partial
Efficacy and safety of the PPARγ partial agonist balaglitazone compared with pioglitazone and placebo: a phase III, randomized, parallel-group study in patients with type 2 diabetes on stable insulin therapy
✍ Kim Henriksen; Inger Byrjalsen; Per Qvist; Henning Beck-Nielsen; Gitte Hansen; B 📂 Article 📅 2011 🏛 John Wiley and Sons 🌐 English ⚖ 357 KB 👁 1 views

## Abstract ## Background Treatment of patients with perioxisome proliferator‐activated receptor‐γ full agonists are associated with weight gain, heart failure, peripheral oedema, and bone loss. However, the safety of partial perioxisome proliferator‐activated receptor‐γ agonists has not been esta